PT - JOURNAL ARTICLE AU - Dimpfl, Thomas AU - Sönksen, Jantje AU - Bechmann, Ingo AU - Grammig, Joachim TI - Estimation of the SARS-CoV-2 infection fatality rate in Germany AID - 10.1101/2021.01.26.21250507 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.26.21250507 4099 - http://medrxiv.org/content/early/2021/01/26/2021.01.26.21250507.short 4100 - http://medrxiv.org/content/early/2021/01/26/2021.01.26.21250507.full AB - Assessing the infection fatality rate (IFR) of SARS-CoV-2 is one of the most controversial issues during the pandemic. Due to asymptomatic or mild courses of COVID-19, many infections remain undetected. Reported case fatality rates – COVID-19-associated deaths divided by number of detected infections – are therefore poor estimates of the IFR. Endogenous changes of the population at risk of a SARS-CoV-2 infection, changing test practices and an improved understanding of the pathogenesis of COVID-19 further exacerbate the estimation of the IFR. Here, we propose a strategy to estimate the IFR of SARS-CoV-2 in Germany that combines official data on reported cases and fatalities supplied by the Robert Koch Institute (RKI) with data from seroepidemiological studies in two infection hotspots, the Austrian town Ischgl and the German municipality Gangelt, respectively. For this purpose, we use the law of total probability to derive an approximate formula for the IFR that is based on a set of assumptions regarding data quality and test specificity and sensitivity. The resulting estimate of the IFR in Germany of 0.83% (95% CI: [0.69%; 0.98%]) that is based on a combination of the RKI and Ischgl data is notably higher than the IFR estimate reported in the Gangelt study (0.36% [0.29%; 0.45%]). It is closer to the consolidated estimate based on a meta-analysis (0.68% [0.53%; 0.82%]), where the difference can be explained by Germany’s disadvantageous age structure. As a result of virus mutations, vaccination strategies, and improved therapy, a re-estimation of the IFR will eventually be mandated; the proposed method is able to account for such developments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for conducting this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used for the empirical analysis are publicly available from the Robert Koch Institute (https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Daten/Fallzahlen_Kum_Tab.html for information on deaths and https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Projekte_RKI/Nowcasting.html for the infection nowcasts; both websites were last accessed on December 12, 2020). The data to calculate the probabilities are taken from the seroepidemiological studies in Ischgl (https://www.medrxiv.org/content/10.1101/2020.08.20.20178533v1) and Gangelt (https://doi.org/10.1038/s41467-020-19509-y), respectively. https://tinyurl.com/Covid19-IFR-DE